Adverum begins next step of wet AMD gene therapy trial

Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular degeneration, Adverum Biotechnologies announced in a press release.

The second cohort of the multicenter, open-label OPTIC trial is receiving an intravitreal injection with a dose of ADVM-022 of 2 × 1012 vg per eye. Safety and tolerability of ADVM-022 at 24 weeks are the study’s primary endpoints.

“We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD. In the first cohort of patients, we have seen a robust preliminary anatomical response and no serious adverse events to date,” Aaron Osborne, MBBS, MRCOphth, Adverum chief medical officer, said in the release.

Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular degeneration, Adverum Biotechnologies announced in a press release.

The second cohort of the multicenter, open-label OPTIC trial is receiving an intravitreal injection with a dose of ADVM-022 of 2 × 1012 vg per eye. Safety and tolerability of ADVM-022 at 24 weeks are the study’s primary endpoints.

“We believe ADVM-022 has potential to provide sustained therapeutic benefit with a single intravitreal injection to patients living with wet AMD. In the first cohort of patients, we have seen a robust preliminary anatomical response and no serious adverse events to date,” Aaron Osborne, MBBS, MRCOphth, Adverum chief medical officer, said in the release.